Processing Your Payment

Please do not leave this page until complete. This can take a few moments.

May 20, 2015

Achillion inks $225M licensing deal

Achillion Pharmaceuticals said it has signed a global licensing agreement with a subsidiary of Johnson & Johnson to develop and commercialize three of the New Haven company’s hepatitis C treatments.

Janssen Pharmaceuticals Inc. will invest $225 million in Achillion and will receive 18.4 million new shares, worth $12.25 each.

In exchange, Janssen will get a worldwide license to develop and commercialize products containing Achillion’s hepatitis treatments, assuming they are approved by regulators.

The agreement includes regulatory and sales milestone payments for Achillion.

Sign up for Enews

Most Recent

Most Recent

0 Comments

Order a PDF